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Background
Chinese hamster ovary (CHO) cells are the most widely
used host for large scale production of recombinant
therapeutic proteins exhibiting high productivities in the
gram per liter range. Although these cells have been
extensively characterized and optimized, a demand to
further increase the performance towards higher pro-
ductivity and clonal stability exists. Up to date, the
clone selection process is mainly based on phenotypic
screens like titer measurements and growth data instead
of more reliable biomarkers. Recently, the genomes of
Chinese hamster as well as of different CHO cell lines
were sequenced, assembled and annotated [1-3]. This
new information gives the opportunity for functional
analysis of the transcriptome and allows rational designs
for the identification of biomarkers for clone selection
and targets for cell line engineering.
Material and methods
CHO-K1a and CHO-C8DEL cell lines were cultivated in
shake flasks in a non-humidified shaker cabinet at 150
rpm, 10% CO2 at 36.5°C in suspension in proprietary,
chemically defined culture media. Cell viabilities and
growth rates were monitored by means of an automated
system (ViCell, Beckman Coulter).
For transient expression plasmid DNA and polyethyle-
nimine “Max” (Polysciences, Eppelheim, Germany) were
diluted into OptiMEM medium (Life Technologies) and
added to the cells after complex formation. The titer of
the model protein in the supernatant was measured by
Protein A HPLC on day 3 and day 6 post transfection.
Cells were stably transfected by electroporation
(Amaxa Nucleofection system, Lonza, Germany) with an
expression plasmid encoding for a human monoclonal
antibody according to the manufacturer’s instructions.
48 h after transfection, selection was started by addition
of geneticin (G418). As soon as cells recovered to a via-
bility of above 80%, a second selection step was applied
by passaging the cells into G418-free medium contain-
ing 1 µM methotrexate (MTX). When the cells resumed
logarithmic growth, cell cultivation was continued in
MTX-containing medium throughout single cell sorting,
screening and productivity assessments. Cells were
stained using a FITC-labeled mouse IgG-anti-human
IgG (BD Pharmingen) and single cell sorting was per-
formed using a FACS-Aria II instrument (Becton Dick-
inson). The 5% most strongly fluorescent cells were
gated and sorted as single cells into 96-well plates. Volu-
metric productivities of G418 and MTX selected pools
and clones were determined by Protein A HPLC in cell
culture supernatants.
Results
Analysis of gene expression profiles of 5-7 high and 5-7
low monoclonal antibody producing CHO-K1a clones of
three different monoclonal antibody projects surprisingly
revealed that the telomeric region of chromosome 8
including several genes is often lost in transfected, high
antibody producing CHO-K1a derived clones. Likewise
surprisingly, a high correlation between the loss of this
telomeric region and increased productivity as well as
clonal stability could be identified in CHO-K1a clones.
The aim of this study was to develop a new parental cell
line lacking this telomeric region. Three of such clones
could be isolated and were named CHO-C8DEL 1-3. The
capability of these isolated, new parental cell lines for cell
line development and protein production was subse-
quently evaluated in depth: Volumetric pool productivities
are significantly increased after transient (Figure 1A) and
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stable transfections (Figure 1C) in the three newly gener-
ated CHO-C8DEL parental cell lines. Additionally, the
drop of cell viability during MTX selection is less pro-
nounced and cells recovered 7-8 days faster from crisis
(Figure 1B). Moreover, significantly more high and stable
producing clones were retrieved after single cell sorting
(Figure 1D), facilitating the screening efforts in order to
obtain a comparable number of high and stable produc-
tion clones. Also, the volumetric productivity(Figure 1E)
as well as stable production over a period of 12 weeks of
the CHO-C8DEL clones is increased (Figure 1F, clones
were classified as stable if they were losing not more than
25% of productivity).
Conclusions
With our study we contribute to the knowledge of how
the recently published CHO genomes [1-3] can be used
to meet the growing demand of industry to further
develop CHO cell lines and to increase their perfor-
mance for the production of new therapeutic proteins in
short time periods.
We compared gene expression profiles of high and
low antibody producing CHO-K1a clones and identified
a subset of genes, localized at the telomeric region of
chromosome 8, which have a role regarding productivity
and production stability. These genes can be used as
biomarkers for selecting high and stable producing cell
lines. In addition, we generated and characterized a new
parental CHO cell line lacking this telomeric region,
which displays several advantageous characteristics for
cell line development and manufacturing.
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Figure 1 (a): Comparison of productivities of an Fc-fusion protein after transient transfection. Average of 3 pools ± STDev.(b): Viabilities
after transfection (day 0) and during selection for three CHO-C8DEL cell lines (green) compared to the CHO-K1a cell line (blue) expressing a
monoclonal antibody. Average of 4 pools ± STDev. (c): After both selection steps a massive increase of productivity of a monoclonal antibody
could be detected for all three CHO-C8DEL lines (green) compared to the CHO-K1a cell line (blue). Average of 4 pools ± STDev.(d): After single
cell cloning of high producing pools of CHO-C8DEL 3 and CHO-K1a, significantly more high producing cells were isolated for the CHO-C8DEL
3 cell line. E: Productivity of 45 best producing CHO-K1a and CHO-C8DEL 3 clones. F: Comparison of stability of 45 best producing CHO-C8DEL
3 clones compared to 37 best producing CHO-K1a clones over a cultivation period of 12 weeks.
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